Conference Description
The 2022 Medicinal Chemistry Gordon Research Conference will feature talks on the cutting edge of the discipline that include new innovations, technologies, and compounds that advance the science. Mike Ellis of Bristol Myers Squibb is responsible for the scientific program; please see the planned topics and contact the Chairs if you would like to submit a talk proposal. A preliminary program of speakers will be posted in December 2021.
In addition to the various scientific sessions, the conference will culminate with a “Late-Breaking Topics” session organized by Meredeth McGowan of MOMA Therapeutics. This session comprises late-breaking results on important clinical candidates across therapeutic areas. Finally, the conference will wrap up on Thursday evening with the Keynote address organized by the Chair.
We strongly encourage attendees to submit poster presentations on any aspect of Medicinal Chemistry as the poster sessions are an essential outlet for thoughtful discussion and interaction among the conferees. This year, the poster sessions will be organized by Matt Volgraf of Genentech.
The 2022 Medicinal Chemistry GRC will continue a tradition of outstanding science presented in a relaxed atmosphere offering a variety of social activities. Vice-Chair Elect Erin DiMauro of Merck will organize social events for the week, including hikes of Mt. Kearsarge and Mt. Cardigan, a Philbrick-Cricenti bog walk, frisbee golf, volleyball, softball, soccer, a golf scramble, and a charity poker tournament.
As we look forward to another fantastic conference in 2022, on behalf of myself, the Vice Chair, and the Vice-Chair Elect, we welcome your application. This conference is typically full by early May. We encourage applications by April 1 and the submission of any poster abstracts by April 15 to facilitate the admissions process. In particular, we encourage applications from those of diverse backgrounds and scientific perspectives.
Thank you for your interest in the Medicinal Chemistry GRC!
Cindy Parrish
GlaxoSmithKline
Chair, 2022 Medicinal Chemistry GRC
The topics, speakers, and discussion leaders for the conference sessions are displayed below. The conference chair is currently developing their detailed program, which will include the complete meeting schedule, as well as the talk titles for all speakers. The detailed program will be available by April 9, 2022. Please check back for updates.
Small Molecule Approaches for Immuno-Oncology
Emerging Technologies: From In Silico to Implementation
Therapies Targeting Diseases of the CNS
Synthetic Technologies to Enable Medicinal Chemistry
Recent Advances in Modulators of Protein-Protein Interactions
Strategies for Overcoming Drug Safety Liabilities
New Directions in Beyond 500 Compounds: From PK to the Clinic
Late-Breaking Topics: First Disclosures of Clinical Candidates
Keynote Session: Unlocking the Dark Genome and Other Uncharted Territories in Drug Discovery
The GRC Power Hour™
Discussion Leaders
Discussion Leaders
-
H. Rachel Lagiakos (Schrödinger, United States)
Discussion Leaders
-
Emily Peterson (Biogen, United States)
Discussion Leaders
-
Amy Hart (Aleksia Therapeutics, United States)
Discussion Leaders
-
Alex Cortez (Bristol Myers Squibb, United States)
Discussion Leaders
-
Izzat Raheem (Merck & Co. Inc., United States)
Discussion Leaders
-
Andrew Scholte (Sanofi, United States)
Discussion Leaders
-
Meredeth McGowan (MOMA Therapeutics, United States)
Discussion Leaders
-
Michael Ellis (Bristol-Myers Squibb, United States)
Speakers
-
Eric Miller (Emory University, United States)
-
Louis Chupak (Bristol Myers Squibb, United States)
-
Nigel Swain (Sosei Heptares, United Kingdom)
Speakers
-
Steve Swann (Exscientia, United States)
-
Falgun Shah (MERCK, United States)
-
Bryce Harrison (Morphic Therapeutic, United States)
-
Heike Schoenherr (Relay Therapeutics, United States)
Speakers
-
Peter Fuller (Merck & Co., Inc., United States)
-
Duane Burnett (Arkuda Therapeutics, United States)
-
Kevin Guckian (Biogen, United States)
Speakers
-
Jesus Alcazar (Janssen Pharmaceutical Companies of J&J, Spain)
-
Rachel Grainger (Astex Pharmaceuticals, United Kingdom)
-
Alison Wendlandt (Massachusetts Institute of Technology, United States)
-
Michelle Hall (Moderna Therapeutics, United States)
Speakers
-
Eric Fischer (Harvard Medical School / Dana Farber Cancer Institute, United States)
-
James Henderson (C4 Therapeutics, United States)
-
Woody Sherman (Roivant Sciences, United States)
Speakers
-
Iyassu Sebhat (Kallyope, United States)
-
Michael Rudd (Merck Research Laboratories, United States)
-
Grace Chuang (Cytokinetics, United States)
-
Patrizio Mattei (F. Hoffmann-La Roche Ltd., Switzerland)
Speakers
-
Matthew Mitcheltree (Merck & Co., Inc., United States)
-
John O Link (Gilead Sciences, United States)
-
Xiaozhang Zheng (Kymera Therapeutics, United States)
Speakers
-
Michael Graupe (Gilead Sciences Inc., United States)
-
Scott Edmondson (Nimbus Therapeutics, United States)
-
Michelle Garnsey (Pfizer, Inc, United States)
-
Maksim Osipov (Denali Therapeutics, United States)
Speakers
-
Rosana Kapeller (ROME Therapeutics, United States)
Conference ID: 11581